JPRN-UMIN000030446
Not Yet Recruiting
N/A
Effect of SGLT2 inhibitor, Dapagliflozin combined with or without metformin on body composition in patients with type 2 diabetes - Effect of SGLT2 inhibitor combined with metformin on body composition
Conditionstype 2 diabetes mellitus
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- type 2 diabetes mellitus
- Sponsor
- St. Marianna University School of Medicine
- Enrollment
- 54
- Status
- Not Yet Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)patients who administrating less than 750mg of metformin 2\)patients who receive insulin injection therapy 3\)hypersensitivity to study drugs on this study, 4\)severe ketosis and diabetic coma or pre\-coma 5\)serious infective diseases, serious injury, pre\- and per\-operation 6\)pregnancy, nursing woman or possibly pregnant woman 7\)moderate or severe renal dysfunction (eGFR: less than 30 mL/min/1\.73m2\) 8\)patients who receive steroids, growth hormone secretagogue, sex hormone agents 9\)patients who are inadequate to enter this study due to the other reasons by physician's judgments
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, Not Recruiting
N/A
Impact of treatment with Dapagliflozin in type 1 diabetic patientsEUCTR2015-002963-40-ESDra Cristina Avendaño Sola
Recruiting
N/A
ong-term effects of dapagliflozin, a SGLT2 inhibitor, on glucose metabolism in patients with type 2 diabetes mellitustype 2 diabetes mellitusJPRN-UMIN000026042Kurume University School of Medicine300
Active, Not Recruiting
Phase 1
Short-term effects of the substance dapagliflozin on the increase of blood sugar concentrations after meal and insulinsensitivity in type 1 diabetic patients.effects of Dapagliflozin on postprandial glucose excursion and fasting glucose homeostasisTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2014-001441-24-ATMedical University Innsbruck12
Active, Not Recruiting
Phase 1
To investigate whether treatment with the SGLT-2 inhibitor dapagliflozin improves the perception of hypoglycemia in people with type 1 diabetes with impaired awareness of hypoglycemiaType 1 diabetesTherapeutic area: Diseases [C] - Hormonal diseases [C19]EUCTR2018-001569-17-NLRadboud university medical center15
Completed
Phase 3
Dapagliflozin in Physical Exercise in Type 1 DiabetesDiabetes Mellitus, Type 1NCT04049110Insel Gruppe AG, University Hospital Bern39